ORIGINAL ARTICLE, globenewswire.com, June 29, 2021
After three years of research and development, Front Line Medical Technologies introduces the world’s smallest REBOA device to control bleeding and help patients survive emergencies
LONDON, Ontario, June 29, 2021 (GLOBE NEWSWIRE) — Front Line Medical Technologies, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its COBRA-OS™ (Control of Bleeding, Resuscitation, Arterial Occlusion System). The COBRA-OS™ is the first 4 French REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta) device and it is the smallest on the market. It is a cost-effective, innovative, easy-to-use aortic occlusion device with an extremely low profile for temporary hemorrhage control and resuscitation.
To continue reading this article CLICK HERE
